PDL BioPharma, Inc. (PDLI) Misses Q2 EPS by 1c

July 27, 2011 5:52 PM EDT
PDL BioPharma, Inc. (NASDAQ: PDLI) reported Q2 adjusted EPS of $0.39, $0.01 worse than the analyst estimate of $0.40. Revenue for the quarter came in at $122.1 million versus the consensus estimate of $123.25 million.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Add Your Comment